Jeffrey Stevens, MD
Retina Specialist · Pasadena, CANPI 1114254711
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 29.0% of the total. 2025 is the largest year on record at $542, more than ten times the $51 reported in 2019. That places this record below the midpoint for retina specialist clinicians in CA, where the typical reported total is $3,667.
Across 66 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$470
- AbbVie$356
- Astellas Pharma US Inc$315
- Genentech USA, Inc.$288
- Alimera Sciences, Inc.$49
- Eyepoint US, Inc.$44
- plus $97 from 4 others
What the payments were for
- Food & beverage$1,619100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 18 | $470 |
| AbbVie(2 entities) | 16 | $356 |
| Astellas Pharma US Inc | 11 | $315 |
| Genentech USA, Inc. | 11 | $288 |
| Alimera Sciences, Inc. | 2 | $49 |
| Eyepoint US, Inc. | 2 | $44 |
| Bayer | 2 | $36 |
| Vyera Pharmaceuticals, LLC | 2 | $33 |
| GSK | 1 | $15 |
| Oyster Point Pharma, Inc. | 1 | $12 |
How this compares
$1,619 in reported general payments places this provider in the 25th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 189 | $6,262 |
| MoxifloxacinMoxifloxacin Hcl | 127 | $4,102 |
| Latanoprost | 238 | $1,831 |
| Brimonidine Tartrate | 72 | $1,381 |
| Ketorolac Tromethamine | 28 | $1,252 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 84 | $878 |
| Ofloxacin | 45 | $545 |
| Timolol Maleate | 37 | $292 |
| Dorzolamide Hcl | 21 | $287 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Pasadena
- Sahar BedroodPasadena$297K
- Payam AminiPasadena$11K
- Eugene ChangPasadena$10K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
- Baruch KuppermannIrvine$1M
- Carlos Medina MendezSacramento$548K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.